Copperwynd Financial LLC Has $445,000 Stake in Axon Enterprise, Inc $AXON

Copperwynd Financial LLC trimmed its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 6.9% in the second quarter, HoldingsChannel.com reports. The firm owned 537 shares of the biotechnology company’s stock after selling 40 shares during the period. Copperwynd Financial LLC’s holdings in Axon Enterprise were worth $445,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after acquiring an additional 185,571 shares during the period. Alliancebernstein L.P. grew its holdings in Axon Enterprise by 15.9% during the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after acquiring an additional 175,890 shares during the period. Westfield Capital Management Co. LP grew its holdings in Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after acquiring an additional 212,931 shares during the period. Northern Trust Corp grew its holdings in Axon Enterprise by 1.2% during the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after acquiring an additional 8,794 shares during the period. Finally, Jennison Associates LLC grew its holdings in Axon Enterprise by 23,203.7% during the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after acquiring an additional 611,418 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $727.41 on Thursday. Axon Enterprise, Inc has a fifty-two week low of $422.21 and a fifty-two week high of $885.91. The stock has a market cap of $57.10 billion, a price-to-earnings ratio of 179.61, a PEG ratio of 27.75 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm’s 50-day simple moving average is $756.79 and its 200 day simple moving average is $710.65.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million for the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter last year, the firm earned $1.20 EPS. The firm’s revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on AXON shares. Northland Securities set a $800.00 price target on Axon Enterprise in a report on Tuesday, August 5th. Wolfe Research started coverage on Axon Enterprise in a report on Monday, July 7th. They set an “outperform” rating for the company. JMP Securities reiterated a “market outperform” rating and set a $825.00 price target on shares of Axon Enterprise in a report on Monday, September 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday, September 24th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $841.64.

Insiders Place Their Bets

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the sale, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. This trade represents a 6.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Hadi Partovi acquired 1,358 shares of the firm’s stock in a transaction on Wednesday, August 13th. The stock was purchased at an average price of $740.00 per share, with a total value of $1,004,920.00. Following the purchase, the director owned 237,938 shares in the company, valued at approximately $176,074,120. The trade was a 0.57% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 59,932 shares of company stock worth $45,115,616 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.